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Abstract
Human cerebral malaria is a severe and often lethal complication of Plasmodium falciparum 
infection. Complex host and parasite interactions should the precise mechanisms involved in the 
onset of this neuropathology. Adhesion of parasitised red blood cells and host cells to endothelial 
cells lead to profound endothelial alterations that trigger immunopathological changes, varying 
degrees of brain oedema and can compromise cerebral blood flow, cause cranial nerve dysfunction 
and hypoxia. Study of the cerebral pathology in human patients is limited to clinical and genetic 
field studies in endemic areas, thus cerebral malaria (CM) research relies heavily on experimental 
models. The availability of malaria models allows study from the inoculation of Plasmodium to 
the onset of disease and permit invasive experiments. Here, we discuss some aspects of our current 
understanding of CM, the experimental models available and some important recent findings 
extrapolated from these models.
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Introduction
Without highly effective antimalarial treatment, death from severe Plasmodium falciparum 
(P. falciparum) malaria ensues just hours following admission to a hospital or clinic [1]. 
More than three billion individuals over a 109 malaria-endemic countries are at risk of 
infection, particularly children under five [2] and non-immune adults. One to two percent of 
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individuals infected with P. falciparum develop severe malaria, with the most serious 
manifestation known as cerebral malaria (CM).
P. falciparum is transmitted to the human host by the female Anopheles mosquito causing a 
debilitating cycle of parasite differentiation, invasion and replication within the red blood 
cell (RBC). Rupture of the RBC and the subsequent release of parasites and their toxins 
activate immunological responses within the host, leading to the manifestation of this 
syndrome. This review addresses the value and application of data extrapolated from in vitro 
and in vivo models of CM to the human syndrome. We have focused on the use of human 
and murine microvascular endothelial cells (MVEC), retinal whole mount preparations and 
primate or, rodent in vivo models to discuss recently discovered parameters such as 
microparticles (MP) and miRNA and less on those that have been extensively reviewed 
previously [3–18].
Human CM: Clinical Signs and Pathophysiological Hallmarks
Immense pressure exists to quickly identify patients presenting with CM, as they are at high 
risk of death following hospital admission. Intensive care monitoring and antimalarial 
treatment is paramount to life saving care, but in resource poor countries where the highest 
mortality rates exist, facilities are severely limited. Those infected face poor prognosis and 
clinicians have a short window period in which to treat before death ensues.
The clinical presentation of CM is influenced by the immune status of the population and 
their level of exposure [19,20]. Notable differences in the presentation of CM exist between 
children and non-immune adults [21]. Typical clinical signs of P. falciparum infection 
include fever, nausea, malaise, anorexia, headache, joint ache and delirium [22]. Coma is the 
most indicative sign of CM as accessed via Blantyre coma score for children and Glasgow 
coma score for adults [22,23]. Other signs include seizures, respiratory distress, 
hypoglycaemia, circulatory collapse, spontaneous bleeding, intracranial hypertension, 
acidosis, prostration and severe malarial anaemia [21]. Surviving patients experience 
neurocognitive deficits particularly with speech and movement, post-infection [24–27].
The diagnosis of CM is based on the presence of unarousable coma, confirmation of 
peripheral parasitaemia and the exclusion of encephalopathies of other causes [28]. Because 
the diagnosis is based on exclusion, CM can be incorrectly considered in the differential 
diagnosis of many viral encephalopathies [29].
The pathogenesis of CM is complex, and manifestations result from interplay between 
several factors including those that relate to transmission parameters, virulence and drug 
sensitivities of P. falciparum as well those relating to the host such as genetics, nutrition and 
immune status.
This neurovascular pathology is characterised by the sequestration of mature parasitised and 
non-parasitised red blood cells (PRBC and NRBC) and other cell types such as platelets and 
monocytes deep within the cerebral microvasculature (Figure 1) [30,31]. Ischemia due to the 
irreversible endothelial damage caused by the intense congestion of the vessels is believed to 
account for the presence of petechial and ring haemorrhages in the brain of infected patients 
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[32]. Widespread endothelial damage by cytokines and parasite toxins result in peri-vascular 
oedema parenchymal necrosis, and neuronal cell death (Figure 2) [33,34].
Human CM: Limitations in Scope of Studies
To delineate the pathogenesis of CM, the timing and sequence of events leading to the 
manifestation must be known. For obvious reasons, human studies are limited to clinical and 
genetic field studies in endemic areas, and study of tissue at end-point, including 
comparative histopathology. These studies of HCM provide valuable descriptive and 
correlative data. Although to demonstrate causality and the underlying immunopathogenesis, 
invasive and interventional studies, which of course are unethical, would be required.
Current imaging technologies such as magnetic resonance imaging (MRI), spectroscopy 
(MRS) and computational tomography (CT) provide a way forward for clinicians to follow 
the progression of the disease [35,36]. Focal parenchymal abnormalities, haemorrhages or 
diffuse cerebral oedema attributed to CM can be detected and facilitate early diagnosis. 
However, these imaging technologies are expensive and their availability in endemic clinical 
settings is limited [22,37]. Ophthalmoscopy is less expensive alternative diagnostic tool used 
to detect malarial retinopathy in patients [38]. It is yet to be widely used but has great 
promise in increasing the precision of the clinical diagnosis of CM [38].
The limitations of human studies mandate the use of experimental models to supplement 
human data. Access to clinical samples is limited for ethical reasons contributing to the 
difficulty in validating data obtained from experimental models. Complementary methods of 
in vivo and in vitro experimental models as well as human studies are required to elucidate 
the mechanisms of pathophysiology in CM.
Models Available to Study CM
In addition to clinical field and ex vivo studies (post-mortem sampling) other approaches to 
studying CM include, in vitro(modelling of CM lesions) and in vivo (animal models of CM) 
models [39]. These model systems are empowering tools that permit the study of the 
sequence of events from the early stages of infection and provide a platform for the testing 
of novel hypotheses. They have facilitated drug testing and vaccine development as well as 
research on mechanisms of host defence and pathogenesis of CM [40]. Here, we have 
chosen to address the in vitro and in vivo experimental model contributions to our 
understanding of HCM, specifically regarding immunopathogenesis.
The disparity between the results extrapolated from ECM and their translation to HCM have 
been a matter of debate. Here we aim to address the value and application of findings 
observed in models of CM to the paediatric syndrome. The use of ECM is justified by the 
number of similarities shared with HCM [5,16]. As reviewed by Hunt and Grau in 2003, the 
neurological signs such as convulsions, paralysis and seizures are similar [8]. A number of 
key histopathological features such as vascular obstruction, parenchymal haemorrhage, 
leukocyte adhesion, oedema and focal demyelination are observed in ECM and in HCM [8], 
with PRBC accumulation substantially less marked in ECM. However, several groups have 
reported evidence for PRBC sequestration in ECM [41–46]. With simplified coma and 
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behavioural scoring for ECM, similar to that routinely used to assess HCM, correlations 
between CM signs and cerebral changes can be made quickly [47,48].
However, the value of murine models, including the PbA model, in contributing to our 
current understanding of the pathogenesis of CM and therapeutic strategies has been 
questioned [49]. The variable incidence of PRBC sequestration, the inability of mice to be 
infected by P. falciparum, and the parasitological differences between human and mouse 
Plasmodium support this idea.
In vitro and ex vivo models
Human and mouse brain microvascular endothelial cells—In vitro models 
simulate the interaction between the endothelium and target cells such as RBC, platelets and 
MP found in the CM lesion. The endothelium of the blood brain barrier (BBB) forms the 
actual site of the CM lesion. Using endothelial cell lines isolated from human, mice and non-
human primates, researchers have represented this interaction in both static and flow assays. 
MVEC have been isolated from many tissues [50], with brain and lung often used to model 
CM lesions, since these organs develop distinct pathology during infection. Although not a 
microvascular cell type, many studies have also used human umbilical cord endothelial cells 
in co-cultures both in static and shear-stress assays [51]. Static assays are technically simple 
and involve the incubation of target cells and/or parasites on subconfluent monolayers of 
endothelium [52]. Following incubation, non-adherent cells are washed off and adherent 
cells are enumerated. These static assays have contributed to our knowledge on 
cytoadherence although they do exclude the effect of shear forces found in blood vessels in 
vivo. Alternatively, flow based assays use laminar flow conditions simulating the 
physiological shear stress of blood vessels. These assays enable the quantitation of adherent 
cells, and allow close study of the receptors and ligands mediating the binding, whilst 
withstanding similar conditions experienced in vivo [52]. These assays can be adapted to 
study cytoadherence on brain, lung and placenta.
Retinal wholemount preparation—Retinopathy is an important clinical sign in adult 
[53,54] and paediatric CM [55]. Retinal pathology was first described in ECM [56], and can 
be detected by ophthalmoscopic examination of CM patients [38]. Recent studies describe 
damage of the optic and trigeminal nerve in ECM, explaining the manifestation of impaired 
visual acuity and neurological signs [57,58]. The retinal and cerebral vasculatures are so 
similar, that the retinal wholemount preparation provides information on the interaction of 
cells within an intact vascular plexus. This model allows the detection of microvascular 
changes such as haemorrhages, congestion and breakdown of BBB in the early stages of 
murine CM, including damage to the microglia and astrocytes [56,59].
In vivo models of cerebral malaria
Available animal models of CM provide a closer approximation to the human response. 
Although they do not reproduce HCM entirely, the key cells that are involved in the 
pathogenesis of HCM, experimental CM (MCM) and the immune response pathways are 
similar. In addition, the clinical signs and cerebral pathology, including the lesions are 
comparable. The most commonly used models of CM have been developed in primates and 
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in rodents [4,39]. The number of models available to study CM pathogenesis is limited in 
comparison to those available to study non-severe malaria.
Primates—The importance of studying Plasmodium infection in primates has been 
heightened due to findings of P. falciparum in wild apes once thought as infecting humans 
only [60]. The cross transmission of Plasmodium between humans and primates questions 
host specificity and invasion strategies of the parasite. Little evidence exists to support 
zoonotic transmissions, although proposals into understanding the extent of the potential are 
underway [61,62]. Emerging evidence for P. knowlesi infection in human, potentially fatal 
malaria, has also supported the transfer of host from primate to human [63].
Previous attempts to produce a model that used the same causative agent as in HCM were 
modest. Infection of the squirrel monkey Saimiri sciureus with P. falciparum, developed 
neurological signs with a fatal outcome, although the model lacked predictability, with 
variable incidence of CM [64]. Other primate models of CM include infection of the rhesus 
monkey (Macaca mulatta) with P. coatneyi [65], P. knowlesi [66] or P. fragile [67], 
whereby infected hosts develop coma and become moribund. Post-mortem examination 
shows characteristic vascular congestion, notably PRBC sequestration within the brain 
microvessels. The overproduction of cytokines (TNF, IFN and IL-1β) and the upregulation 
of adhesion molecules (CD36, thrombospondin and ICAM-1) are seen in these models, 
mimicking pathological hallmarks of the human syndrome [68]. Although contributing to 
knowledge on some aspects of CM, primate model use is limited by their high cost, ethical 
restrictions and lack of genetically modified animals available.
Rodents—Mouse models of CM are the most commonly used in vivo experimental model 
[39]. Several mouse models exist in which infection is induced with Plasmodium infected 
RBC including P. yoelii 17XL [69], PbA [70–72] P. berghei NK65 [73] and PbK173 [74]. 
Each model exhibits specific characteristics, P. yoelii for instance infects preferentially 
reticulocytes while the others infect mature RBC. PbA mouse model has many advantages 
that not only include the availability of genetically susceptible and resistant mouse strains, 
but also the ability to reproduce clinically evident neurological signs within a precise time 
course. Infection of CM-susceptible mice (CBA and C57BL/6) with P. berghei ANKA 
(PbA) results in reproducible fatal CM, 7 to 14 days later. PbA infection of CM-resistant 
mice, such as the DBA/2 and BALB/c strains, results in NCM, with mice succumbing to 
hyperparasitaemia and severe anaemia 3 weeks later. The availability of KO strains and the 
relatively inexpensive breeding and housing of the mice is also an advantage. For practical 
and ethical reasons rodent models are commonly used to study CM.
The Contribution of Experimental Models to our Understanding of CM 
Pathophysiology
PRBC sequestration and cytoadherence
Sequestration of P. falciparum-infected RBC in the microvasculature, particularly small 
capillaries and post-capillary venules, is a signature of HCM [75–77]. P. falciparum 
schizonts, trophozoites as well as mature gametocytes tether and roll to adhere to host 
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receptors. By adhering to the endothelium, RBC and parasites are removed from the 
circulation and consequently escape clearance by the spleen, effectively implementing their 
survival strategy. Analysis of post-mortem tissue from individuals who died of CM show 
parasite sequestration within the brain, lung, spleen, intestine, skin, fat tissue and muscle 
[78].
During P. falciparum infection the ability of PRBC and NRBC to squeeze through 
capillaries is impaired. The sequestration of the PRBC decreases the luminal diameter and 
the ability of erythrocytes to deform becomes very crucial to the capillary flow rate. RBC 
that become more rigid, plug capillary lumens already obstructed with sequestered PRBC. 
The growth of the parasite within the host erythrocytes modifies its shape by increasing the 
internal viscosity of the cell and exerts oxidative stress on the cell through release of by-
products such as lactic acid. Coupled with rosetting, this obstruction leads to decreased 
tissue perfusion and localised hypoxia that continues the onslaught of the endothelium.
Knob proteins provide a point of attachment and have been long known to mediate parasite 
sequestration in P. falciparum malaria [79]. Although evidence does exist for knobless 
cytoadherence [80–82], suggesting other mechanisms may also contribute to this 
phenomenon. The absence of knobs does not necessarily diminish their ability to cytoadhere 
[80] validating the study of mouse PRBC, that do not display the knobbly phenotype.
The mousemodels of CM have received criticism for their inability to clearly demonstrate 
the sequestration phenomenon in the brain as seen in HCM. One study with P. berghei 
ANKA infection in (BALB/c× C57BL/6)F1 mice, has clearly shown morphological 
evidence of PRBC and leucocyte sequestration in the brain, in a pattern similar to what is 
observed in HCM [41]. The accumulation of PRBC was also observed in the brain of PbA 
infected C57BL/6 mice [44]. Technically, detecting P. berghei sequestration in vivo is 
challenging. P. berghei infections are usually in asynchronous parasite stages, some stages 
of the cycle are indistinguishable including multiple parasite infections of a single RBC 
incorrectly identified as a schizont [9,43]. This hampers their detection in routine peripheral 
blood smears and in tissue histology. Schizonts are absent from peripheral blood smears of 
infected mice and only ring stages, trophozoites and gametocytes can be detected. Even 
technical aspects such as perfusion may also shroud the real quantitation of PRBC 
sequestration [44]. Also, PRBC sequestration in ECM is relatively short-lived, occurring in 
the final 20 hours [42], and most studies are limited by ethical constraints preventing death 
as the end-point.
In vitro assays using mouse brain MVEC have provided direct in vitro evidence for 
cytoadherence of RBC from P. berghei ANKA (PbA) and P. berghei K173 (PbK173)-
infected mice on brain endothelial cells [83]. PRBC infected with P. yoelii 17XL also adhere 
to mouse brain MVEC [70].
From these assays the interaction of PRBC, monocytes, platelets and the CD36 receptor on 
MVEC [84,85] as well as the ICAM-1 [85], VCAM-1 and E-selectin receptors [86] has been 
described. Flow assays have confirmed the complexity of cytoadherence with a number of 
cell-adhesion molecules and selectins being implicated in the process of tethering, rolling 
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and firm adhesion [87,88]. Understanding the variations in binding avidity to host ligands 
[89] and the pathways involved in the reversal [90] or inhibition of binding is important in 
finding new therapeutic strategies.
The site where the vascular endothelial cells are isolated from affects the gene expression 
and responsiveness to Plasmodium, thus it is important to hone in on relevant organ 
endothelium [77,91,92]. For example, differences exist in the mediation of cytoadherence 
between PRBC and the endothelium of the brain, lung and placenta. Specifically, it is known 
that the sequestration of PRBC in the placenta is mediated by variant surface antigens 
(VSA) specific for CSA, in mice and human pregnancy-related malaria [91,93]. Although, 
recent studies using flow cytometry-based adhesion assays, have revealed parasite adhesions 
other than VSA specific for CSA may also be involved [94]. Despite rodent parasites not 
expressing PfEMP1 homologs, mouse models of placental malaria are still informative.
The association of sequestration and clinical presentation is clear in HCM, although the 
causal relationship is not. Despite mouse models being criticised for not clearly 
demonstrating parasite sequestration, no evidence exists to suggest that the severity of HCM 
is related to the degree of cytoadherence [95,96].
With advancement in luciferase-based live imaging technology, evidence exists for the 
sequestration of PbA schizonts in the spleen, lung and adipose tissue [97], supporting the 
observation of organ entrapment of rodent parasites P. chabaudi chabaudi, P. vinckei pettier, 
P. yoelii schizonts [43,98]. The real-time in vivo imaging of these transgenic bioluminescent 
P. berghei parasites has enabled insight into the sequestration phenomenon in mice [97,99] 
as well as sporozoite interactions with host immune cells within the liver [100,101].
Parasite ligands and host endothelial receptors directly mediating sequestration of P. 
falciparum proteinaceous knobs on the outer membrane of RBC, erythrocyte membrane 
protein 1(EMP1) encoded by P. falciparum enable PRBC to bind multiple receptors such as 
CD36, intracellular adhesion molecule 1(ICAM-1), vascular adhesion molecule 
1(VCAM-1), chondroitin sulphate A(CSA) and endothelial-cell selectin (E-Selectin) 
[102,103]. In the mouse model, CD36 has been identified as the major receptor for schizont 
sequestration in lung and spleen [9,97,99]. Although no CD36 mediated schizont 
sequestration is observed in mouse brain, evidence exists for the close association of PRBC 
to the brain endothelium, closely resembling what is seen in HCM [41]. It is still unclear 
what mediates the sequestration of parasites in the mouse brain, although it has been shown 
that CD36 expressing platelets, monocytes and macrophages may facilitate the 
cytoadherence by serving as a bridge between the parasite and endothelium [104,105]. No 
clear association between the binding of CD36 and PRBC and the severity of disease exist 
[96,106–108]. Only sparse detection of CD36 in cerebral vessels exist, with no evidence for 
up regulation in human cerebral malaria [109].
Endothelial protein biomarkers such as angiopoietin-1 and 2, soluble Tie-2, von Willebrand 
factor (vWF), vascular endothelial growth factor (VEGF), soluble ICAM-1 (sICAM-1) are 
predictors of paediatric CM. More specifically, higher levels of vWF and vWF pro-peptide 
indicate acute endothelial cell activation in patients with malaria [110]. We now know that 
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vWF is capable of mediating the adhesion of PRBC to the endothelium via platelet 
decorated ultra-large vWF strings [51]. In vitro flow assays using P. falciparum PRBC and 
human umbilical vein endothelial cells demonstrated this adhesionvia CD36-dependent 
platelet bridging and reversal was achieved by treatment with vWF proteases [51].
ICAM-1 is a major adhesion molecule on the endothelium that has been described to 
participate in the adhesion of PRBC to the endothelium. Upregulation of ICAM-1 
expression has been observed in cerebral vessels of patients who died with CM [109]. 
ICAM-1-mediated sequestration of PRBC in HCM has been shown [108] and parasites 
isolated from children with CM showed the highest binding to ICAM-1 under flow 
conditions [107]. This has been confirmed on brain MVECs from patients with CM, in vitro 
[77]. Contact of PRBC with the endothelium mediated partially by ICAM-1, induces 
diffusion of malaria antigens from parasite to the endothelium and transmigration-like cup 
formation, that progressively covers and engulfs the PRBC [111]. In addition to ICAM-1, 
PRBC form interactions with receptors CD36, P-selectin and VCAM-1 to varying degrees of 
strength under flow conditions [87].
Several reports of focal leucocyte recruitment in HCM [112,113] quell reports that murine 
models over represent the role of leucocytes in CM. Accumulation of monocytes [48,114], T 
cells and platelets in brain venules of PbA infected mice parallels what is observed in 
paediatric HCM [115] as well as adult CM [114]. Endothelial co-cultures with P. falciparum 
demonstrate the potential for leucocyte recruitment [77,116,117].
Total parasite burden is a better indicator of disease severity. Parasite biomass accumulation 
within the tissue microvasculature is strongly associated with the onset of ECM [44,46] and 
HCM [118]. Higher parasite load is found in the brain of PbA compared to PbK173-infected 
mice [119]. CM-susceptible mice infected with PbK173, do not develop CM, but succumb 
to hyper-parasitaemia and anaemia approximately 14 days post-infection [120,121]. This 
parasite is used to study murine non-cerebral malaria (NCM), and resembles the pulmonary 
pathology seen in humans, particularly with malaria-associated ARDS [122]. The 
mechanism by which the parasite contributes to the pathogenesis is not straight forward. 
Although, it’s postulated that the parasite is responsible for the direct obstruction of 
microvessels following sequestration in target organs and cause anaemia through their 
invasion of RBC.
Cerebral oedema—Although coma in HCM is not caused by cerebral oedema [76], brain 
swelling and herniation still remain characteristic of CM [123,124]. In ECM, MRI studies 
revealed the characteristic brain oedema along with parenchymal lesions, BBB breakdown 
and arterial flow perturbations [125]. This oedema contributes to the compression of 
cerebral arteries and nerves, perturbing the blood flow and causing cranial nerve dysfunction 
[57]. Histologically, enlarged perivascular spaces (PVS) are signs of brain oedema that are 
significantly more numerous in mice with CM [126]. Interestingly, PVS are associated with 
an overexpression of aquaporin-4 (AQP4) on astrocytic foot processes particularly in 
infected mice showing signs of neurological involvement [126] but a recent study using 
AQP4 KO mice suggests that this molecule does not have a role in CM pathogenesis and 
might be protective [127]. In HCM, although not significant, a trend towards higher AQP4 
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was found in Vietnamese adult patients with CM [76]. This trend may be significant if 
studied in paediatric CM, since it resembles ECM more closely.
Hypoxia—In murine CM vascular obstruction impedes blood flow leading to ischemia, and 
consequently contributing to the pathogenesis of CM [128]. Intravital microscopy has 
revealed that ECM is associated with microvascular dysfunction, vascular collapse and 
decreased blood flow [129]. Interestingly, hypoxic foci are more pronounced in murine CM 
compared to NCM and reversal of tissue hypoxia can be achieved by injection of the 
hypoxia-responsive hormone, erythropoietin (EPO) [130]. EPO stimulates nitric oxide (NO) 
production improving tissue perfusion and oxygenation in vivo [131]. It is well established 
that NO in CM, modulates endothelial activation, decreases the expression of endothelial 
adhesion molecules and inhibits monocyte, platelet and PRBC adhesion [132–134]. 
Inducible synthesis of NO by the mosquito limits parasite growth [135], although direct 
treatment with NO does not reduce parasite growth, even at saturable levels [136]. In ECM, 
NO is not required for the development of the cerebral syndrome [137] and exogenous NO 
is protective [134]. Nitric oxide treatment reduces ICAM-1, P-selectin in the brain of PBA 
infected mice, and maintains the integrity of the BBB [134]. However, low bioavailability of 
NO contributes to the development of the syndrome in ECM [138]. In HCM, data support a 
deleterious role of NO [139] as well as protective [140]. Review of current data on NO has 
supported a hypothesis that supplemental inhaled nitric oxide (iNO) is a solid candidate for 
the adjunct treatment of CM [141].
Molecules and Cells Involved in CM Pathogenesis
Cytokines and chemokines
Post infection, the susceptible host undergoes a Th1 response whereby over expression of 
TNF, lymphotoxin (LT) and IFN exacerbates the progression to CM [142]. The 
overproduction of TNF and it deleterious role in CM was described in ECM and confirmed 
in HCM [143–145]. TNF induces alterations in the endothelium [146], mediates the 
upregulation of adhesion molecules, induces apoptosis [147] and the further release of 
cytokines and chemokines and also triggers the reorganisation of plasma membrane [148]. 
In human clinical trials, although patients did develop CM anti-TNF monoclonal antibody 
attenuated the malaria fever [149]. In C57BL/6 mice, TNF deficiency does not confer 
protection from CM [150] suggesting other mediators may also be contributing to the 
syndrome.
Since the first report of raised serum levels of LT in human CM [151], studies have shown 
that LT and not TNF is the principle mediator of murine CM [150]. LT deficiency in 
C57BL/6 mice conferred complete protection against CM [150]. Produced only by 
lymphocytes, LT and TNF are thought to work synergistically to induce hypoglycaemia and 
increased serum levels of interleukin-6 in severe malaria [151]. These overlapping functions 
of LT and TNF indicate that several mediators are responsible for the development of CM.
Early IFN production correlates with protection from CM and this early peak is absent in 
mice with CM [152]. However, late production of IFN is essential for the development of 
the syndrome [153]. IFN mice on CM-susceptible backgrounds are resistant to CM 
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[154,155]. IFN influences T cell effector function and it is essential for CD4+ T cell 
activation, which may underlie the resistance of IFN mice to CM [156]. Incubation with 
IFN, increases the expression of TNF receptors [157] and the synergistic relationship 
between TNF and IFN has been demonstrated [158]. Recent studies have shown that 
neutralisation of IFNβ increased survival, reduced ICAM-1 and T-cell infiltrates in the brain 
[159].
Murine models of CM have allowed investigations into host-dependent mechanisms. 
Different mouse strains exhibit different sensitivities to Plasmodium infection and there is 
increasing evidence for genetic basis for susceptibility to CM [160] and the sensitivities of 
brain endothelium to cytokines [77,161]. PbA infection in CM-susceptible and resistant 
mouse strains, allow comparison in their differential responsiveness. Clinical resistance to 
malaria is associated with low production capacity of IFN [162]. Brain MVECs isolated 
from CM-resistant and sensitive mice exhibit different sensitivities to TNF [161] as did 
brain EC derived from patients with CM and those with uncomplicated CM [77]. Gene 
analysis studies of CM-susceptible and -resistant mouse strains revealed several molecular 
differences in early infection [163]. Variation in host gene expression may ultimately be 
responsible for susceptibility to infection, influencing the clinical course of malaria. 
Infection with PbA significantly alters the expression of genes involved in metabolic energy 
pathways at the time of CM [164]. This is consistent with observations of brain metabolic 
perturbations by way of hypoxia, hypoglycaemia and inadequate use of oxygen observed in 
HCM.
Platelets—In vivo and in vitro studies have supported a pathogenic role for platelets in CM 
[164–168]. Post-mortem sampling of brain from patients with CM showed greater 
accumulation of platelets and a higher proportion of vessels with platelets than brain from 
patients with severe malarial anaemia or non-malarial encephalopathies [169]. Close study 
of the CM lesion using platelet-EC assays show platelets binding to and activating the 
endothelium and engaging in the release and transfer of substances that may exacerbate the 
development of the syndrome [170]. The interaction between platelets and the endothelium 
dramatically modulates gene expression in vitro on human EC [171] particularly of 
cytokine-, chemokine-, TGFβ-, death-receptor-, apoptosis-, erythropoietin-and TREM1-
signaling pathways and potentiates cytotoxic functional changes on activated endothelium 
[166]. In addition, PRBC interact with CD36 expressed on platelets [172] and in synergy 
with TNF to induce transcriptional changes in EC [171]. Other platelet receptors gC1qR/
HABP1/p32 [108] and CD31 [173] have also been identified as supporting the interaction 
between platelets, PRBC and endothelial cells. Imaging using a platelet-specific contrast 
agent revealed cytokine mediated differential platelet binding to the endothelium at earlier 
stages of the disease than once described using MRI [174]. As reviewed previously, platelets 
act as bridges between the endothelium, fibrinogen and PRBC, secreting mediators and 
exerting their effects at the interface of the BBB [86]. As described later in section 7, even 
platelet-derived microparticles enhanced P. falciparum-infected erythrocytes binding and 
altered EC functions similar to their parent cell [175].
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T cells—Other host cells such as monocytes and T cells are active players in the 
pathogenesis of CM. The importance of the role of monocytes in CM pathogenesis has been 
reviewed previously [176]. Both CD4+ and CD8+ T cells have been implicated in HCM and 
ECM pathogenesis [177–179] and athymic nude mice do not develop CM [179]. Helper T 
lymphocytes are also involved in the pathogenesis of CM, contributing to the development 
of cerebral lesions with microvessel plugging and haemorrhages [70,179]. Depletion of 
CD4+ and CD8+ T cells reduced parasite biomass, and mice did not develop CM [44]. The 
concomitant presence of T cells and PRBC in the brain is critical for sequestration and the 
onset of CM [42,45]. CD8+ T cells accumulate in the liver in ECM, although their 
contribution to the progression of disease is most prominent in the brain [180]. Another line 
of evidence supporting this is that CD8+ T cells but no PRBC were found sequestered in the 
brains of mice infected with a non-CM causing parasite [42]. This was also supported in 
data from CM-resistant mice, where lower accumulation of PRBC and no sequestration of 
CD8+ T cells was observed in BALB/c mice [42]. Early evidence for leukocyte involvement 
in HCM [181] was later confirmed in the brains of patients who had died of CM 
[106,182,183].
MicroRNA—The host resistance and response to malaria is complex. Mouse models have 
allowed some insight into what influences susceptibility and the exploration of genes that 
may provide resistance to infection [11]. They have also enabled closer study of gene 
regulatory molecules involved in CM pathogenesis [118]. MicroRNA (miR)-150, miR-127 
and let-7i, implicated in the innate immune response, apoptosis and monocytic proliferation 
were modulated in ECM but not in NCM [118]. Although CBA and C57BL/6 mice develop 
CM, they display differences in their expression of miRNA post-infection [118]. This 
suggests that strain differences may be a factor in gene expression regulation and this may 
have implications for the study of HCM, particularly with respect to differences in genetic 
makeup.
MP as Modulators of CM
Extracellular vesicles such as exosomes and MP have now been described as having roles in 
cell-cell interactions, antigen presentation and immune modulation in malarial infections 
[184–187]. However, so far most of studies have been made on the role MP can have as 
biomarkers and in the development of the disease via their interactions with target cells. 
Exosomes are 30–100 nm membrane vesicles derived from the endosome that carry parasite 
proteins and are able to elicit protective immune responses in ECM [184]. MP are larger 
membrane vesicles (100 nm to 1 μm) produced following cell activation and apoptosis due 
to cell membrane remodelling and loss of phospholipid asymmetry. During vesiculation, 
structural proteins are distorted, phospholipids are reorganised, and specifically through the 
‘flip flop’ phenomenon phosphatidylserine (PS) migrates from the inner leaflet to the outer 
leaflet. The role of MP in the pathogenesis of CM has been elucidated by clinical findings 
and supported by in vivo and in vitro studies [185–187]. Normal baseline levels of MP are 
present in healthy individuals although elevated levels of circulating endothelial MP have 
been detected in the plasma of Malawian children with acute P. falciparum malaria [115]. 
Elevated levels of platelet, RBC and leucocyte-derived have been observed in patients with 
P. vivax malaria [188]. In Cameroonian patients, elevated levels of MP were detected from 
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EC, monocytes, platelets and RBC in adult patients with CM [189]. Platelets released the 
highest levels of MP and this correlated with depth of coma and thrombocytopenia in P. 
falciparum-infected patients [190] and the length of acute illness and the presence of fever 
in P. vivax patients [188]. This finding is consistent with the presence of platelet 
accumulation in cerebral microvessels in HCM and ECM [105,190]. Interestingly, PMP 
transferred platelet antigen to PRBC and not to normal RBC and increased the PRBC 
cytoadherence to the endothelium [175]. Uptake of PMP by the endothelium induced 
changes in EC phenotypes [117,175]. Plasma concentrations of RBC derived MP were 
highest in patients infected with P. falciparum, compared with P. vivax and P. malariae 
infected and healthy patients [191]. This supports a role for MP in the exacerbation of 
disease.
Data collected in human studies have also been confirmed in murine CM and NCM. 
Interestingly, low baseline circulating MP levels were detected in non-infected mice, and 
subsequently raised upon CM onset [172]. Furthermore, phenotypic analyses showed that 
circulating MP were predominantly from platelet, endothelial and RBC origin. Mice with 
NCM displayed different production patterns of MP, distinct to CM mice, again supporting a 
role for MP in the cerebral syndrome.
TNF is an inducer of MP production in vitro [192], thus the associated elevated levels of MP 
during infection may be related to TNF overproduction [145]. Purified MP from mice with 
CM displayed significantly enhanced pro-coagulant and pro-inflammatory properties 
compared to healthy mice [172]. In addition these MP have adhesive properties, suggesting 
a potential pathogenic role in vivo [172].
Functional loss of ATP-binding cassette A-1 (ABCA-1) on the plasma membrane disables 
the cells ability to respond to agonists thus decreased the number of circulating MP and 
conferring protection against CM [172]. Prevention of CM by pantethine treatment in PbA 
infected mice also decreased plasma MP production [193]. Incubation with citicoline, a 
membrane stabiliser, prior to TNF stimulation prevents the vesiculation of MP in vitro and 
confers some protection in vivo when administered as adjunct therapy, in combination with 
artesunate [194,195].
Conclusions
Current scepticism about the relevance and use of murine models of malaria [50] has 
prompted a number of responses [16,40,196,197]. Some researchers voiced that this 
scepticism may affect grant funding and research publication that utilise experimental 
models [6], thus impinging on the progress of our understanding on this disease. Others 
called to facilitate better communication between scientists who utilise human studies and 
those that use experimental studies, sometimes involving the same people [6,13]. A number 
of recommendations have been made to improve translation of experimental data into 
clinical studies including the standardisation of models across all species and the creation of 
human tissue biobanks [13].
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Appreciating the value of these models, and acknowledging their limitations would facilitate 
better research approaches to close the gap on CM. There are similarities between ECM and 
HCM to justify their use, although caution in the interpretation and application of the 
findings is paramount. Ultimately, the driving force for the study of HCM is the patient’s 
welfare and this can only be upheld by realistic translation of experimental findings.
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Representative diagram of the microvascular lesion underlying the development of CM. 
Infection with P. falciparum induces the production of cytokine and chemokines, activates 
EC lining blood vessels and upregulates cell-adhesion molecules. PRBC and host cells such 
as RBC, platelets and leukocytes adhere to vessel walls through the interaction of ligands 
and receptors. The release of MP, malarial products, toxic mediators and the activated 
endothelium, together facilitate the adhesive cellular interaction within the vessel lumen 
leading to microvascular obstruction. The arrested cells impinge on the integrity of the blood 
brain barrier, disrupt tight junctions, cell viability and function leading to oedema and 
possible haemorrhages.
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Endothelial-mediated cellular cross talks underlie immunopathological mechanisms in CM. 
Following upregulation of EC surface receptors and engagement with PRBC, the PRBC-EC 
interaction continues with a diffusion of membrane elements and the formation of tight 
transmigration (TM)-like cups. TNF and IFNγ are known to modulate MHC II expression 
shown to be related to the genetic susceptibility to CM. MHC II expression on the 
endothelium enables the take up of P. falciparum antigens supporting their role as antigen 
presenting cells and also supporting and stimulating T cell proliferation in vitro. The 
continued production of cytokines stimulates the release of pro-inflammatory, pro-coagulant 
MP from host cells. MP express antigens from their cell of origin as well as negatively 
charged phospholipids, triggering additional cellular interactions in the inflammatory 
response such as cell adhesion, permeability and cell death. MP can be found along the inner 
vessel wall at the site of PRBC-platelet accumulation. Platelets accumulate via von 
Willebrand factor (vWF) strings or adhesion receptors such as ICAM-1. Excessive cross-
talk between tethered platelets, EC and their MP progeny induces alteration of the BBB 
integrity, promotes the secretion of cytokines and increases the adhesiveness which in turn 
fuels the exacerbating cycle.
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